MaxCyte Webinars

  1. Audience Q&A | Inside The Most Promising Non-Viral Approaches To Genetic Engineering 11/9/2024

    Expert panelists, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics, provided detailed responses to our audience questions on electroporation, CRISPR, delivery technologies beyond LNPs, CAR T-cell therapy, and more.

  2. Electroporation As A Method For Genetic Modification 11/9/2024

    In this clip, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics explain why electroporation has a higher gene editing efficiency than that of the viral vector method.

  3. NK Cells' Role In Non-Viral Approaches To Genetic Engineering 11/9/2024

    Here, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their take on the primary challenge to modifying NK cells.

  4. Base Editing's Advantages When Combined With Non-Viral Delivery Methods 11/9/2024

    In this segment, Paul Kopesky of Beam Therapeutics shares information on the advantages base editing has over other gene editing approaches when combined with non-viral delivery methods as well as how Beam addresses the challenge of achieving therapeutic levels of editing and target tissues using non-viral delivery systems.

  5. Safety And Efficacy Advancements In Genome Editing 11/9/2024

    Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics shares his take on the high frequency of productive edits for base editing. In addition, Celularity’s Chairman, Founder, and CEO, Dr. Robert Hariri, shares how he sees non-viral gene delivery methods potentially enhancing cell therapy platforms.

  6. Non-Viral Tools For Genome Engineering 11/9/2024

    In this segment, Dr. Robert Hariri, Chairman, founder, and CEO of Celularity, and Paul Kopesky, Ph.D., VP of Cell Therapy Process Development at Beam Therapeutics each share their own take on the tools, platforms, and non-viral approaches they have used for genome engineering of cell therapeutics.

  7. The State Of CRISPR And Gene Editing Presentation 8/2/2024

    Listen in on this session from The State of CRISPR and Gene Editing Summit which focus on the use of CRISPR-based therapies in clinical settings using electroporation. 

  8. Scalable Cell Transfection Technology From Concept To Manufacturing 8/2/2024

    Improve your gene editing and cell manufacturing with electroporation platforms and gene editing technology.

  9. GMP-Compliant, Scalable Electroporation Platform For Non-Viral Cell Engineering 8/2/2024

    This presentation explores natural killer (NK) cells and how conditions for electroporating primary NK cells can be optimized to improve cell viability, transfection efficiency, and other factors.

  10. Gene Editing In Hematopoietic Stem Cells For Monogenic Blood Cell Diseases 8/2/2024

    Explore Cas9-mediated homology-directed repair and advancements in gene editing technologies that could significantly broaden the treatment possibilities for various blood disorders.